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Studies indicate that environmental exposure to lead is
associated with reduced renal function. Whether lead affects
progressive diabetic nephropathy is unclear. Eighty-seven
patients with type II diabetes and diabetic nephropathy
(serum creatinine of 1.5–3.9 mg/dl) with normal body lead
burden and no lead exposure history were observed over a
12-month period. Thirty subjects with high normal body lead
burdens (80–600 lg) were randomly assigned to a chelation
and control group. For 3 months, the 15 chelation-group
patients underwent lead-chelation therapy with calcium
disodium ethylenediaminetetraacetic acid weekly until body
lead burden fell o60 lg, and the 15 control group subjects
received a weekly placebo. During the following 12 months,
renal function was regularly assessed at 3-month intervals.
The primary outcome was an elevation of serum creatinine to
1.5 times baseline value during the observation period. A
secondary outcome was temporal changes in renal function
following chelation therapy. Twenty-six patients achieved the
primary outcome. Basal blood lead levels and body lead
burden were the most important risk factors in predicting
progressive diabetic nephropathy. Following chelation, the
rates of decline in glomerular filtration rates in the chelation
group and the control group, respectively, were 5.075.7 ml
and 11.877.0 ml/min/year/1.73 m2 of body surface area
(P¼ 0.0084) during follow-up, although both groups had
similar rates of progression of renal function during the
12-month observation period. We concluded that low-level
environmental lead exposure accelerates progressive
diabetic nephropathy and lead-chelation therapy can
decrease its rate of progression.
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The relationship between heavy long-term lead exposure
and chronic interstitial nephropathy is well recognized.1–3
Several epidemiological studies4,5 have identified a positive
correlation between blood lead levels and age-related
decreases in renal function in the general population,
indicating that environmental lead exposure decreases
renal function in healthy persons. However, those studies
did not address other factors potentially related to progres-
sive renal function deterioration such as daily urinary protein
excretion, daily protein intake, etc. Moreover, blood lead
levels only represent recent lead exposure and do not indi-
cate body lead burden.6–8 The most reliable methods of
measuring body lead burden are X-ray fluorescence studies
of bone lead content and calcium disodium ethylenediamine-
tetraacetic acid (EDTA) mobilization tests.9 A body lead
burden 4600 mg (2.90 mmol), as determined by calcium
disodium EDTA mobilization, is deemed lead poisoning.
A previous study by the same authors utilized EDTA mobili-
zation tests to assess body lead burden in non-diabetic
chronic renal insufficiency patients without history of
lead exposure;10–15 analytical results demonstrated that
environmental lead exposure accelerates progressive renal
insufficiency.
The incidence of diabetes mellitus, particularly type II
diabetes, is increasing worldwide. Current estimate claims
that 410% of the United States population is16 affected
by diabetes mellitus and accounts for 440% of all cases
with end-stage renal disease. Additionally, the number of
patients starting renal replacement therapy in US has grown
exponentially over the past 20 years. Cases of end-stage renal
disease attributed to diabetes, especially type II diabetes,
accounted for the majority of this increase.17 A recent
prospective epidemiological study,18 which published after
this study was begun, analyzed changes in renal function in
relation to baseline lead levels, diabetes, and hypertension
among 448 middle-aged men over a 6-year period. That
study suggested that both blood lead levels and bone lead
content are associated with progressive increase of serum
creatinine in diabetic patients. As other epidemiological
studies, failing to adjust for daily urine protein excretion and
glycosylated hemoglobin confounds their findings. However,
the association between environmental lead exposure and
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progressive renal insufficiency in patients with type II
diabetes and diabetic nephropathy requires elucidation.
This prospective study assessed whether chronic low-level
environmental lead exposure increases the rate at which
diabetic nephropathy progresses and whether lead-chelation
therapy slows this progression in the type II diabetic patients.
RESULTS
Longitudinal observation period
Eighty-seven patients completed the 12-month observation
period (59 men and 28 women) (Figure 1). The following
baseline data were obtained: patient mean age was 60.0710.0
years (range, 33–79 years); body-mass index (weight in
kilograms divided by the square of height in meters) was
25.473.2 (range, 19.6–33.4); serum creatinine level was
2.170.5 mg/dl (185.6–44.2 mmol/l; range, 1.5–3.8 mg/dl
(132.6–344.7 mmol/l)); creatinine clearance rate was 38.57
11.6 ml/min/1.73 m2 of body surface area (range, 16.6–
68.0 ml/min/1.73 m2 of body surface area); estimated glome-
rular filtration rate was 35.179.0 ml/min/1.73 m2 of
body surface area (range, 14.1–59.1 ml/min/1.73 m2 of body
surface area); daily protein excretion was 3.172.5 g (range,
0.5–12.2 g); daily protein intake was 0.9670.17 g/kg (range,
0.60–1.63 g/kg); blood lead level was 6.573.4 mg/dl (0.287
0.15 mmol/l; range, 1.6–19.1 mg/dl (0.07–0.82 mmol/l)); and,
body lead burden was 108.5753.8 mg (0.4770.23 mmol;
range, 29.6–373 mg, 0.13–1.62 mmol)). Blood lead level
correlated to body lead burden for all patients (r¼ 0.306,
P¼ 0.0044). Fifty-seven patients (63.2%) had hyperlipid-
emia. Eighty-six patients (98.9%) had hypertension, that in
239 type II diabetes with serum Cr 1.5 and 3.9 mg/dl,
without previous lead exposure
93 without laser therapy for diabetic retinopathy,
18 micro-hematuria, 14 daily urine protein excretion
<0.5 g/day, 11 small-sized kidneys, three body lead burden
>600 g and 10 met exclusion criteria excluded
90 patients entered into the 12-month obervation
period
Two lost follow-up, and
one died of acute myocardial infarction
87 completed the 12-month observation period
Nine without diminished renal function at the end of
observation period, 26 body lead burden < 80 g,
16 serum creatinine > 3.9 mg/dl and six without
written informed consents excluded
30 with BLB 80 g and < 600 g
and serum Cr 1.5 and 3.9 mg/dl randomized
15 assigned to study group,
received 3-month lead chelation
15 assigned to placebo group,
received 3-month placebo therapy
15 completed the 12-month follow-up 15 completed the 12-month follow-up
Figure 1 | Flow chart showing the enrollment and status of patients.
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84 patients (96.6%) was treated with angiotensin-converting
enzyme inhibitors or angiotensin II receptor antagonists.
Fifteen patients (17.2%) smoked. All patients had retinopathy
that was treated with laser therapy. Among all study patients,
25 (28.7%) had a history of cardiovascular diseases, including
myocardial infarction, stroke and diabetic foot.
At the end of the 12-month observation period the
following data were obtained: serum creatinine level was
2.971.0 mg/dl (229.87106.1 mmol/l; range, 1.5–5.9 mg/dl
(132.6–521.6mmol/l)); creatinine clearance rate was 28.97
15.4 ml/min/1.73 m2 of body surface area (range, 8.3–72.1
ml/min/1.73 m2 of body surface area); and, estimated
glomerular filtration rate was 25.3710.1 ml/min/1.73 m2 of
body surface area (range, 14.6–59.1/min/1.73 m2 of body
surface area). Twenty-six patients (29.9%) achieved the
primary end point during the observation period; none,
however, required hemodialysis. Only two of these 26 sub-
jects had body lead burdens of o80 mg. Cox regression
analysis demonstrated that – after adjusting for other factors –
history of cardiovascular disease, baseline mean arterial
pressure, baseline daily urinary protein excretion, and body
lead burden were significant risk factors for progression
of renal insufficiency associated with diabetic nephropathy
in type II diabetic patients (Table 1).
Body lead burdens and blood lead levels are the most
powerful predictors of progressive decline in renal function.
Longitudinal multivariate analysis with a generalized estimat-
ing equation of data for all patients revealed that body lead
burden and high blood lead levels were the only significant
predictors of a progressive reduction in the glomerular
filtration rate. Each increase of 100 mg (0.48 mmol) in body
lead burden caused a reduction in the glomerular filtration
rate of 7.2 ml/min/1.73 m2 of body surface area (Po0.0001)
(Table 2). Moreover, after adjustment for other relating
factors, each increase of 1 mg/dl (0.043 mmol/l) in blood
lead levels resulted in a reduction in the glomerular filtration
rate of 0.56 ml/min/1.73 m2 of body surface area during the
observation period (P¼ 0.0280).
Intervention period
Chelation therapy. In total, 30 patients with a high-
normal body lead burdens were enrolled in the intervention
trial. Patients were randomly assigned to two groups, each
with 15. The chelation group underwent chelation therapy
for 3 months and the control group received a placebo. Both
groups had similar baseline characteristics with the exception
of borderline significant differences for renal function indices
(Table 3). Following 3 months of lead-chelation therapy,
body lead burden in the chelation group reduced to 49.47
12.2 mg (0.2470.06 mmol; range, 6.2–60 mg (0.03–0.29 mmol)),
and blood lead levels decreased to 4.171.2 mg/dl (0.207
0.06 mmol/l; range, 1.6–12.1 mg/dl (0.08–0.59 mmol/l)). The
therapeutic dosage of calcium disodium EDTA averaged
7.073.0 g (range, 4–14 g). After chelation therapy, the change
in the glomerular filtration rate in the chelation group was
0.675.2 ml/min/1.73 m2 of body surface area, compared with
1.474.6 ml/min/1.73 m2 of body surface area in the control
group (P¼ 0.3952 by the Mann–Whitney U-test).
Table 1 | Cox regression analysis of the overall risk of the
primary outcome of progressive renal insufficiency,
according to baseline prognostic factors
Variable
Hazard ratio
(95% CI)a P-value
Age (each increment of 1 year) 0.97 (0.91–1.04) 0.3738
Female sex 1.56 (0.49–4.96) 0.4473
Smoking 0.57 (0.17–1.92) 0.3629
Use of insulin injection 0.96 (0.32–2.65) 0.8799
Previous cardiovascular diseases 3.35 (1.08–10.36) 0.0362
Baseline body-mass index (each
increment of 1)
0.81 (0.68–0.91) 0.0227
Mean arterial pressure (each increment
of 1 mm Hg)
1.07 (1.02–1.11) 0.0026
Baseline serum creatinine (each
increment of 1 mg/dl (88mmol/l))
1.36 (0.36–5.15) 0.6523
Body lead burden (each increment of
1 mg)
1.01 (1.01–1.02) 0.0011
HbA1c (%) (each increment of 1%) 0.92 (0.72–1.18) 0.5200
Cholesterol (mg/dl) (each increment of
1 mg/dl)
1.01 (1.00–1.02) 0.1011
Baseline daily protein intake (each
increment of 1 g/kg)
5.29 (0.28–100.0) 0.2668
Baseline daily protein excretion (each
increment of 1 g)
1.34 (1.07–1.69) 0.0115
aCI denotes confidence interval. The body-mass index is the weight in kilograms
divided by the square of the height in meters. The primary end point was defined as
an increase in the serum creatinine level to 1.5 times the baseline value during the
observation period.
Table 2 | Longitudinal analysis of body lead burden and other
predictors of progressive change in the glomerular filtration
rate, using generalized estimating equations, during the
12-month longitudinal study period
Variable
Estimate
(interactive
effect)a P-value
Age (each increment of 1 year) 0.0644 0.4635
Sex (female versus male) 1.3816 0.4171
Smoking (no versus yes) 0.1437 0.9447
Use of insulin injection (no versus yes) 0.7757 0.6428
Previous cardiovascular diseases
(no versus yes)
4.2014 0.2282
Baseline body-mass index (each increment
of 1 kg/m2)
0.4575 0.0755
Mean arterial pressure (each increment
of 1 mm Hg)
0.4394 0.0987
Baseline serum creatinine (each increment
of 1 mg/dl (88mmol/l))
9.2452 0.4678
Body lead burden (each increment of 1 mg) 0.0719 o0.0001
HbA1c (%) (each increment of 1%) 0.2383 0.5456
Cholesterol (mg/dl) (each increment
of 1 mg/dl)
0.0078 0.6518
Baseline daily protein intake
(each increment of 1 g/kg)
5.6975 0.2398
Baseline daily protein excretion
(each increment of 1 g)
0.3952 0.2800
HbA1c: glycosylated hemoglobin.
aThe interactive effect of variables was calculated by a generalized estimating
equation. Negative values for the interactive effect indicate a decline in the
glomerular filtration rate, and positive values indicate an increase.
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Table 3 | Baseline characteristics of patients with high normal body lead burden in the control and study groups at the
beginning of the clinical triala
Variable The control group The study group P-value
(N=15) (N=15)
Age (year)
Mean7s.d. 57.977.1 59.5712.6 0.6322
Range 47–66 33–79
Sex (no. of patients)
Male/female 13/2 11/4 0.6513b
Body-mass index (kg/m2)
Mean7s.d. 26.373.7 25.972.9 0.7521
Range 21.0–32.8 21.5–30.3
HBA1c (%)
Mean7s.d. 8.371.9 8.571.3 0.7217
Range 5.5–12.0 5.6–13.3
Use of insulin at entry (no. of patients) (%) 4 (26.7) 6 (40.0) 0.6999w
Serum creatinine (mg/dl)b
Mean7s.d. 2.770.5 3.070.5 0.0748
Range 1.7–3.6 2.2–3.9
Creatinine clearance rate (ml/min/1.73 m2)
Mean7s.d. 28.678.6 23.177.9 0.0767
Range 17.6–46.0 9.9–35.6
Glomerular filtration ratec (ml/min/1.73 m2)
Mean7s.d. 26.376.2 22.474.4 0.0572
Range 17.2–41.8 14.8–30.8
Blood lead (mg/dl)d
Mean7s.d. 5.972.2 7.574.6 0.2477
Range 2.4–10.4 1.8–17.0
Body lead burden (mg)d
Mean7s.d. 131.4777.4 148.0788.6 0.7217
Range 81–373 95–217.4
Daily protein excretion (g)
Mean7s.d. 4.072.3 3.972.0 0.9209
Range 0.5–8.2 0.5–10.7
Daily protein intake (g/kg)
Mean7s.d. 0.9370.17 0.9570.12 0.7321
Range 0.75–1.20 0.51–1.20
Hyperlipidemia (no. of patients) (%)e 11 (73.3) 10 (66.7) 0.9999w
Use of statin drugs (no. of patients) (%) 10 (66.7) 9 (60.0) 0.9999w
Hypertension (no. of patients) (%)f 15 (100) 14 (93.3) 0.9999w
Use of angiotensin-converting enzyme inhibitors or angiotensin-receptor
antagonists (no. of patients) (%)
15 (100) 14 (93.3) 0.9999w
Use of nondihydropyridine calcium channel blockers (no. of patients) (%) 3 (20) 5 (33.3) 0.6817w
Use of dihydropyridine calcium channel blockers (no. of patients) (%) 6 (40) 7 (46.7) 0.9999w
Smoking (no. of patients) (%) 3 (20) 6 (40) 0.6817w
Previous myocardial infarction (no. of patients) (%) 3 (20) 1 (6.7) 0.5977w
Previous stroke (no. of patients) (%) 3 (20%) 3 (20) 0.9999w
HbA1c: glycosylated hemoglobin; MDRD: Modification of Diet in Renal Disease.
aA high-normal body lead burden was defined as a lead value of at least 80 mg (0.39 mmol) but o600 mg (2.9 mmol).
bTo convert values for serum creatinine to micromoles per liter, multiply by 88.4.
cGlomerular filtration rate was calculated by the MDRD formula.
dTo convert values for lead to micromoles per liter, multiply by 0.04286.
eHyperlipidemia was defined as a serum cholesterol level above 240 mg per deciliter (6.2 mmol per liter) after diet control.
fHypertension was defined by the presence of at least two blood pressure measurements above 140/90 mm Hg in a patient who was receiving antihypertensive drugs.
wP-values were calculated by Fisher’s w2 test, except in the comparisons of age, body-mass index, serum creatinine, creatinine clearance, glomerular filtration rate, blood lead
level, and body lead burden, which were calculated by Student’s t-test.
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Follow-up period
No significant differences were noted between the two groups
throughout the study period for body-mass index, mean
arterial pressure, glycosylated hemoglobin, serum cholesterol
level, daily urinary protein excretion, or daily protein intake.
Progression of renal insufficiency (5.075.7 ml/min/year)
following initial chelation therapy in the chelation group
was slower than that (11.877.0 ml/min/year, P¼ 0.0084) of
the control group for at minimum 12 months (Table 4).
Conversely, the rate of decline in the glomerular filtration
rate for both groups (control group: 10.777.0 ml/min/year
versus chelation group: 12.777.2 ml/min/year, P¼ 0.4679)
was similar during the observation period (Figure 2). Neither
chelation nor control group patients were lost during the
final 12 months of the follow-up period.
DISCUSSION
Analytical results demonstrated that basal body lead burdens
and blood lead levels, even when at low levels, were major
risk factors in diabetic nephropathy progression in type II
Table 4 | The means of renal function during the 27-month of study period
Renal function (ml/min/1.73 m2) The control group (N=15) The study group (N=15) P (95% CI)
Basal observation period (months 0–12)
Month 0
Ccr 38.978.9 36.479.1 0.4575 (4.3–9.2)
GFR 37.079.2 35.177.5 0.5471 (4.4–8.2)
Month 3
Ccr 35.979.0 33.079.0 0.3929 (3.9–9.6)
GFR 33.578.5 30.377.3 0.2745 (2.7–9.1)
Month 6
Ccr 32.479.8 30.376.6 0.4984 (4.1–8.3)
GFR 30.379.8 29.375.7 0.7465 (5.2–6.9)
Month 9
Ccr 31.477.9 31.7712.2 0.9465 (7.9–7.4)
GFR 27.176.2 26.673.8 0.8039 (3.4–4.3)
Month 12
Ccr 28.678.6 23.177.9 0.0787 (0.6–11.2)
GFR 26.376.2 22.474.4 0.0572 (0.1–7.9)
Rate of decrease of renal function (ml/min/year) during the observation period
Ccr 10.275.5 13.376.6 0.1583 (7.6–1.5)#
GFR 10.777.0 12.777.2 0.4679 (7.4–3.0)#
Initial lead chelation period (months 12–15)
Increased renal function (ml/min) after initial 3-month lead-chelation therapy
Ccr 0.376.3 3.877.8 0.1840 (9.4–1.2)#
GFR 1.474.6 0.675.2 0.3952 (5.7–1.7)#
Post-lead chelation period (months 15–27)
Month 15
Ccr 28.378.9 26.9711.6 0.7102 (6.3–9.2)
GFR 24.976.5 23.077.1 0.4675 (3.4–7.1)
Month 18
Ccr 25.378.6 23.878.5 0.6269 (4.9–7.9)
GFR 20.775.5 22.076.0 0.5519 (5.6–3.0)
Month 21
Ccr 22.778.8 22.7712.5 0.9987 (8.1–8.1)
GFR 18.775.0 19.875.7 0.5880 (5.1–2.9)
Month 24
Ccr 19.378.7 22.9711.6 0.3456 (11.3–4.1)
GFR 16.075.0 19.777.5 0.1308 (8.4–1.1)
Month 27
Ccr 15.378.4 22.1711.7 0.0787 (14.4–0.8)
GFR 13.174.5 18.077.3 0.0352 (9.5–0.4)
Rate of decrease of renal function (ml/min/year) after the chelation
Ccr 13.076.3 4.877.3 0.0010 (3.1–13.3)#
GFR 11.877.0 5.075.7 0.0084 (2.0–11.6)#
Decrements of renal function (ml/min) at the end of clinical trial
Ccr 13.377.7 1.079.8 0.0011 (5.7–18.9)#
GFR 13.277.6 4.476.9 0.0045 (3.4–14.2)#
Ccr: creatinine clearance rate; GFR: glomerular filtration rate.
Data were measured by the Student’s t-test except #data by Mann–Whitney method.
Po0.05 means significant differences.
Kidney International (2006) 69, 2049–2056 2053
J-L Lin et al.: Lead chelation and diabetic nephropathy o r i g i n a l a r t i c l e
diabetic patients. The correlation between environmental
lead exposure and progressive diabetic nephropathy was dose
dependent, even after potentially related covariates were
comprehensively adjusted. These findings are similar to those
obtained in previous epidemiological work,18 which found
that a longitudinal decline of renal function among middle-
aged individuals was dependent on both basal bone and
blood lead levels; this effect was most pronounced in diabetic
patients. However, this study is able to draw a more support-
able conclusion than before as factors related to progressive
renal function were adjusted during analyses and diabetic
patients with possible primary renal diseases were strictly
excluded. Mean blood lead level of this study patients was
6.5 mg/dl, a level similar to those obtained in a nationwide
survey of blood lead levels in Taiwan (7.7 mg/dl)19 and is
situated between that of general population in Europe
(11.4 mg/dl)4 and America (2.8 mg/dl).5 Mean body lead
burden was 108.5mg, far less than the upper normal limit
(blood lead level was o20 mg/dl (0.97 mmol/l) in Taiwan and
body lead burden was o600 mg (2.90 mmol)).10 This study
suggested that a single course of chelation therapy can signi-
ficantly retard progression of diabetic nephropathy for at
least 1 year, even when other treatable factors are controlled.
These analytical findings indicate that chronic low-level
environmental lead exposure can accelerate the progression
of diabetic nephropathy in patients with type II diabetes.
Notably, no safe limits for lead indices were identified in
this work. The influence of body lead burden on progressive
renal insufficiency was more pronounced in diabetic nephro-
pathy patients than in non-diabetic chronic renal disease
patients; that is, each increase of 100 mg (0.48 mmol) in body
lead burden reduced the glomerular filtration rate by 7.2 ml/
min/year/1.73 m2 of body surface area, 24 times a previously
published reduction in the glomerular filtration rate in non-
diabetic patients.15 This analytical finding is similar to that of
recent study for a general population,18 which demonstrated
that an increase in the basal bone lead content from mid-
points of the lowest to highest quartiles was associated with an
age-related increase in the rate of increase in serum creatinine
per year (a 17.6-fold greater increase in diabetics than in non-
diabetics). Furthermore, each increase of 1mg/dl (0.043mmol/l)
in the blood lead levels reduced the glomerular filtration rate
by 0.56 ml/min/year/1.73 m2 of body surface area. This work
indicated that blood lead level is also a predictor of progressive
diabetic nephropathy, which can be easily monitored in clinical
practice. Large population studies20,21 also identified a strong
correlation between measured blood lead levels and body lead
burdens, when environmental lead exposure remained con-
stant. Since environmental lead exposure is commonly neglec-
ted and is potentially preventable, removal of lead sources and
avoiding potential environmental lead exposure, particularly
for patients with diabetic nephropathy, are crucial public
health issues.
Whether increased body lead burden is the cause or a
consequence of chronic renal insufficiency is under debate.22
However, most studies have determined that high body lead
burden is a causal factor for, rather than a consequence of,
reduced renal function.20,23–26 A previous study23 demons-
trated that no differences existed in blood lead levels or
bone lead contents in 188 persons with normal renal function
or mild to severe renal dysfunction. Other studies also
demonstrated that impaired renal function does not cause an
increase in body lead burden or blood lead levels and that
chronic renal failure does not effect lead accumulation.20,24–26
The rate of diabetic nephropathy progression in the
chelation group following chelation therapy was markedly
slower than that in the control group and only approximately
40% of the initial progression rate during the observation
period. Although renal function in the control group was
superior to that in the chelation group at the beginning of the
clinical trial, at study end, renal function in the control group
was significantly worse than that in the chelation group.
These analytical findings indicate that lead-chelation therapy
slows diabetic nephropathy progression in patients with type
II diabetes and high-normal body lead burdens, even when
they have received all currently available treatments to retard
progressive renal insufficiency. A small dose of calcium
disodium EDTA at lengthy intervals has been extensively
applied for chronic renal disease patients and nontoxic
effects were observed.15,20 Lead-chelation therapy reportedly
improved renal function in an animal study of long-term
low-level lead exposure,27 an investigation of lead nephro-
pathy in lead workers,2 and a study of non-diabetic patients
with chronic renal disease;11 the mechanism accounting for
the improvement in renal function by lead-chelation therapy,
however, remains unclear. Environmental low-level exposure
to lead can increase oxidation stress causing functional nitric
oxide deficiency28 and activation of the renin–angiotensin–
aldosterone system in animals and humans.29 Lead chelation
reduces levels of reactive oxygen species associated with nitric
oxide inactivation, enhancing the availability of nitric oxide
to the vascular smooth muscle or inhibiting rennin and
angiotensin II activity, thereby potentially improving renal
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Figure 2 | Estimated mean (72 s.e.) glomerular filtration rate
according to time in the chelation group (N¼ 15) and control
group (N¼ 15) during the study period. The patients in the
chelation group received chelation therapy from month 12 to 15.
#P¼ 0.0572 and *P¼ 0.0352 by Student’s t-tests.
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function following body lead removal. However, substantial
research is required to clarify the lead-chelation mechanism.
EDTA chelation removes other metals, such as zinc,
copper, etc. However, patients with history of exposure to
lead or other heavy metals were excluded from this study.
Additionally, rare studies noted that exposure to low-level
EDTA chelatable ions other than lead affect renal function.
Conversely, considerable evidence in animal and human
studies4,5,10–15,27 indicated that low-level lead exposure results
in kidney injury. Hence, suggesting that removing body lead
slowed progressive diabetic nephropathy is reasonable.
The use of creatinine clearance to assess altered renal
function may limit this study’s results. However, an investi-
gation into the glomerular filtration rate by Levey et al.30
demonstrated a strong correlation between estimated glome-
rular filtration rate and isotopic glomerular filtration rate
(r2¼ 0.91). Another limitation is this study’s relatively short
duration. However, rapidly progressing renal insufficiency –
about 10 ml/min/year – due to the strictly selective criterion
of diabetic nephropathy and relative low basal glomerular
filtration rate made performing a long-term study impossible.
In conclusion, this prospective study suggested that chronic
low-level environmental lead exposure accelerates deteriora-
tion of renal insufficiency in type II diabetic patients with
diabetic nephropathy. Moreover, lead-chelation therapy slows
rapid progression of diabetic nephropathy in patients with
high-normal body lead burdens, when other treatable factors
are controlled. As diabetes is the leading cause of end-stage
renal disease in many countries, these findings are important.
MATERIALS AND METHODS
Subjects
The Medical Ethics Committee of Chang Gung Memorial Hospital
(CGMH), Taipei, Taiwan, approved study protocol. Each patient
provided informed written consent.
Patients aged 30–80 years with type II diabetes mellitus and
nephropathy who received follow-up at CGMH for 41 year were
enrolled if they met all of the following criteria: a serum creatinine
concentration between 1.5 mg/dl (132.6mmol/l) and 3.9 mg/dl
(344.8mmol/l); daily urinary protein excretion of 40.5 g/day; no
micro-hematuria present in urinalysis tests; normal-sized kidneys by
echograms; history of retinopathy with laser therapy by an ophthal-
mologist; and, diabetes for45 years and no history of exposure to lead
or other heavy metals (body lead burden of o600mg (2.90mmol)), as
measured by EDTA mobilization testing and 72-h urine collection.
Diagnosis of diabetic nephropathy was also based on renal histological
examination findings when a renal biopsy was performed.
Exclusion criteria were as follows: type I diabetes; renal insufficiency
with a potentially reversible cause such as malignant hypertension,
urinary tract infection, hypercalcemia, or drug-induced nephrotoxic
effects; presence of other systemic diseases such as connective-tissue
diseases; use of drugs that may affect the course of renal disease, such
as nonsteroidal anti-inflammatory agents, steroids, immunosuppres-
sive drugs or aristolochic acid-containing herbal drugs; previous
substantial exposure to lead (lead poisoning or occupational
exposure); drug allergies; and, absence of informed consent.
Blood pressure of each patient was maintained at o140/90 mm
Hg with diuretics and angiotensin-converting enzyme inhibitors or
angiotensin II receptor antagonists, with or without calcium-blocking
agents and/or vasodilators. Patients with systolic blood pressure
o100 mm Hg were not administered angiotensin-converting enzyme
inhibitors or angiotensin II receptor antagonists. Calcium carbonate
was prescribed to maintain phosphate levels. No patients received
vitamin D3 supplements or erythropoietin treatment. Each patient
underwent a dietary consultation. A diabetic diet (35 kcal/kg of body
weight/day) with normal-protein intake (0.8–1.0 g of high biological
value protein/kg of body weight/day) was recommended for each
patient. A nutritionist reviewed the dietary intake of each patient
every 3–6 months. A 24-h urea excretion was assessed every 3 months
for nitrogen balance and dietary compliance.31 Subjects who did not
return for regular clinical assessments were contacted by telephone or
home visits during the study period.
Measurements of blood lead levels and body lead burden
Blood lead levels and body lead burden were measured as described
previously.15,16,32 Body lead burden was measured utilizing EDTA
mobilization tests modified by Behringer et al.30 Urinary excretions
(72 h) – after the intravenous infusion of 1 g of calcium disodium
EDTA (edetate calcium disodium (Calcium Disodium Versenate),
Abbott Laboratories, North Chicago, IL, USA) – were used to
measure body lead burden. Blood lead and urine lead levels were
determined by electro-thermal atomic-absorption spectrometry
(model 5100 PC, Perkin-Elmer, Boston, MA, USA) with Zeeman
background correction and an L’vov platform. Both internal and
external quality-control procedures applied throughout this study,
achieved consistently satisfactory results. A certified commercially
prepared product (Seronorm Trace Elements, Sero AS, Billingstads,
Norway) was utilized to monitor intra-batch accuracy and ensure
inter-batch standardization. The coefficient of variation for lead
measurement was p5.3%. External quality control was maintained
via participation in two major programs: the governmental National
Quality-Control Program, and an international program adminis-
trated by the College of American Pathologists.15
Study protocol
Baseline data collection period (months –6 to 0). Baseline
blood lead levels, hemoglobin levels, and body lead burdens were
assessed for 6 months prior to the study for the 90 patients enrolled.
Serum creatinine, blood urea nitrogen, potassium, glycosylated
hemoglobin, fasting blood sugar and cholesterol, urinary protein,
creatinine, and urea excretion were measured at 3-month intervals
during the pre-study 6-month period and throughout 27-month
study period using an auto-analyzer system (Hitachi, Tokyo, Japan)
to ensure that entry criteria were met. All study patients received
standard treatment of diabetes, including dietary, blood pressure,
sugar, hyperlipdemia, and body weight control.
Longitudinal observation period (months 1–12). All biochem-
ical data were measured at 3-month intervals starting at months
0–12. Each urinary excretion value was the average from two
consecutive 24-h urine collection samples. Renal function was
assessed utilizing creatinine clearance and estimated glomerular
filtration rate21 (both in ml/min/1.73 m2 of body surface area). The
formula of estimated glomerular filtration rate33 is 198 (serum
creatinine)0.858 (age)0.167 (0.882 if patient is a women) (1.178
if patient is a black) (blood urea nitrogen)0.293 (urine urea
nitrogen)0.249. In total, 87 patients completed initial study period.
Intervention period (months 12–15). The 12-month observa-
tional investigation was followed by a 3-month single-blind randomi-
zed placebo-controlled study. Based on previous works,12,15,32
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a high-normal body lead burden was defined as at minimum 80 mg
(0.39mmol) and o600mg (2.90 mmol) of lead. Thirty patients with
high-normal body lead burdens and serum creatinine levels
o4.0 mg/dl (353.6mmol/l) were randomly assigned to a control
or chelation group. During the first 3 months, chelation group
patients received 2-h weekly intravenous infusions of one vial (1 g)
of calcium disodium EDTA mixed with 200 ml of normal saline
until body lead burden was o60 mg (0.29 mmol). Control patients
received weekly 2-h infusions of one vial (20 ml) of 50% glucose
mixed with 200 ml of normal saline over a period of 5 weeks.15
Follow-up period (months 15–27). Laboratory measurements
were conducted at 3-month intervals for an additional 12 months
after initial placebo or chelation therapy to document possible
changes in renal function.
Outcome measures
The primary end point was an elevation in serum creatinine –
measured twice, each 1 month apart – to 1.5 times that at baseline or
need for hemodialysis during the 12-month observation period.
A secondary end point was temporal changes in renal function
following chelation therapy.
Statistical analysis
The sample size was calculated with PASS software (power analysis
and sample-size package, NCSS statistical software). For a two-tailed
test with a 0.05 significance level, a sample size of 30 patients (15 per
group) was deemed adequate to permit detection of differences
between treatment groups for rate of change to the glomerular
filtration rate of 0.31 ml/min per 3-month interval,11 with a power
of 40.80. Randomization was utilized with the random-digit
method and was based on computer-generated numbers.
The Cox proportional-hazards model was applied to determine
the significance of variables for predicting the primary end point
during the observation period. This model consisted of all variables
identified in literature as related to renal insufficiency progres-
sion.7,8,17 Generalized estimating equations were employed in
longitudinal multivariate analyses using SAS statistical software
(Version 6.12) to further assess a variable’s association with renal
insufficiency progression during the observation period. Differences
in rates of progression for renal failure between the two groups were
analyzed via a w2 test combined with Fisher’s test, and Student’s
t-test. The Mann–Whitney U-test was employed for data not
normally distributed. A simple linear regression analysis was used
to identify the relationship between blood lead level and body lead
burden. All P-values were two tailed, and all results are presented as
means7s.d. A value of Po0.05 was statistically significant.
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